Zimmer Biomet Holdings, Inc. (ZBH) — 分析摘要
Zimmer Biomet Holdings, Inc.（ZBH）的市值为19.25十亿美元，最近一年的营收同比增长了+7.2%。净利润率为8.6%。当前市盈率为23.9倍。
核心要点
- 营收同比变化+7.2%
- 净利润率8.6%
- 市盈率23.9倍
与ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES板块的其他公司相比，ZBH的营收增长为+7.2%，市盈率为23.9倍。
Zimmer Biomet Holdings, Inc. (ZBH)
更新 — ET · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示无重大红旗
基于最新财报，没有触发重大的信用、利润率或趋势红旗。
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
行业
ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
员工人数
17,000
总部
WARSAW, IN
Exchange
XNYS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
年度每股股息
$0.96
股息收益率
0.95%
股息历史
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。